Curlim

Curlim is a late pre-clinical biotechnology company focused on developing innovative therapies for hereditary peripheral neuropathies and neurodegenerative diseases, with a primary focus on Charcot-Marie-Tooth disease type 1A (CMT1A). Founded in 2024 as a spin-off from the University of Limoges, the company utilizes a proprietary cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanodrug platform. This encapsulation technology is designed to improve the solubility, stability, bioavailability, and cellular penetration of active pharmaceutical ingredients (APIs). Curlim's lead candidate, CLM001, is a next-generation nanodrug that encapsulates curcumin to target oxidative stress, endoplasmic reticulum stress, and inflammation, showing promising results in preclinical models without observed toxicity.